Back to the road of anti -cancer and go to a new journey -the 20122 antibody coupling new era forum is grandly held

*For medical professionals for reading reference

Gathering the big coffee, talk about the development of antibodies coupled drugs, and start the new journey of anti -tumor treatment in the future.

In recent years, the development of antibody coupling drugs has been in full swing. As a new and heavy -duty "weapon" in the field of malignant tumors, it has brought surprises to countless doctors and tumor patients, and also created a miracle of life.

On June 11, 2022, the "2022 Antibodies Puppet New Age Forum" kicked off. This conference was sponsored by the China Anti -Cancer Association. It was forum in the field of main forums and breast tumors, forums in the field of lung cancer, precision diagnosis and treatment forum, and pharmacy forum. Composition of sub -forums, Academician Yu Jinming, Dean of Shandong Cancer Hospital, Academician Xu Binghe, Academician Xu Binghe of the Academy of Medical Sciences, gave a speech. Professor Lu Shun, Professor Jiang Zefei, Deputy Director of the Department of Cancer Medical Department of the General Hospital of the PLA, and Professor Cheng Ying, Secretary of the Party Committee of Jilin Provincial Oncology Hospital, were chaired by different links in the conference. Participate in active discussions, and the meeting attracted nearly 50,000 experts to watch the live broadcast during the meeting. At this conference, the participating experts reviewed the development process of antibody coupling drugs, and explained the latest diagnosis and treatment progress and future exploration of tumor targeted therapy. It also explores the opportunities and challenges brought by clinical and pathology of antibody puppet drug innovation of malignant tumor treatment. Participating experts collided and the style showed a wonderful academic feast to scholars in the majority of fields.

Hundred years of journey-

Bring new options for tumor treatment

Most tumor patients go through chemotherapy during treatment, but they are limited by chemotherapy drugs without different attacks on normal tissue, and their drug concentrations in the tumor are insufficient and leading to severe adverse reactions. The antibody coupling drugs of the new action mechanism have emerged, bringing new choices to tumor treatment. The so-called antibody-Drug-Conjugates drug, that is, antibody coupling drugs, is a drug made of antibodies, cytotoxic drugs and coupling bridges. Among them, antibodies will specifically identify and guide drugs to reach the lesion, and coupling can generally break in the pH environment of the lesion, thereby releasing cytotoxin with therapeutic effect. Cytic toxin mainly targets DNA and microtubin of cancer cells to block the proliferation function of tumor cells, thereby inducing apoptosis.

It is understood that the research and development process of antibody puppets dates back to a century ago. The father of immunology Paul Ehrlich first proposed the concept of "Magic Bullet -Magic Bullet", that is, selectively transport toxic drugs to target cells [1]. In 1958, the immunologist Georges Mathé first used anti -rats of white blood cellular immunoglobulin and methotrexate to the treatment of leukemia. The concept of antibody coupling was first proposed [2].

In 1975, molecular biologists Georges J.F. KöHler and César Milstein created hybrid tumor technology on the basis of natural hybrid technology, and for the first time to prepare monoclonal antibodies, driving the development of antibodies. [3] In 1983, the first antibody coupling drug human clinical trial was successful. In 2000, the world's first antibody puppet drug, MyLotarg, was approved to be listed. In 2013, T-DM1, the first antibody coupling drug for solid tumors, was approved. Today, a total of more than 10 antibody coupling products in the world are listed, and more than 200 clinical trials are under research.

"Just as the theme of the conference of the conference in the future, the prevention and treatment of tumors accompanied by the new anti -tumor drugs including antibody coupling drugs to enter a new chapter. , Overall cancer's 5 -year survival rate is not less than 46.6%. It is necessary to increase the 5 -year survival rate of tumor patients by 15%. In order to achieve this prevention and treatment goal, the country has actively encouraged innovation in recent years and actively promoted the reform of the medical system. Drugs have been accelerated. The new generation of antibody coupling drugs have excellent performance in multiple cancer treatment explorations. At the just ended 2022 American Clinical Tumor Annual Conference (ASCO), antibody couplet drugs are even more riding. Dust, released a number of heavy research results to help the treatment of tumor reaching a new height. I hope that these drugs that urgently need clinical need to benefit from Chinese tumor patients earlier. I hope that in the future clinical diagnosis and treatment work The value of treatment benefits more families and helps healthy China 2030. "Academician Yu Jinming said.

"Since the first antibody coupling drugs have been approved, we are experiencing unprecedented development, especially the structural innovation gives new type of antibody even more effective and specific, not only on the basis of existing standard treatment It further improved the curative effect, and broke through the existing therapeutic concept, creating greater the treatment value for tumor patients. "Academician Xu Binghe added that" but it is worth noting that in addition to the upsurge Drugs are highly homogeneous in the old -fashioned competition in the drug. I hope that researchers and drug research and development institutions will actively expand the choice of different targets, seek differentiated development, adhere to clinical value -oriented, and avoid duplicate and resources waste. Finally With the continuous efforts of all parties to help the achievement of the 2030 goals together. "New breakthroughs-

Open a new pattern of tumor treatment

Today, antibody coupling drugs have displayed excellent clinical efficacy in the fields of breast cancer, gastric cancer, urinary epithelial cancer, lung cancer, and hematological tumors. It has become the fourth ladder drug of tumor after chemotherapy, targeted and immunotherapy. At present, the research and application of antibody coupling drugs has become a hot spot in the field of precision treatment in tumor.

Professor Shao Zhimin introduced: "By exploring for many years in the field of antibody coupling drugs, we gradually realize that the complexity of antibody coupling drugs must be effectively pushed together to develop targets, loads, connectors, and antibodies to develop successful. Antibody coupling drugs. Starting from the first generation of antibody coupling drugs, through continuous structural innovation, the new generation of antibody couples has been given stronger effect and higher specificity. Judging from the clinical study of the drug head opposite, the new generation of antibody coupling drugs significantly extended the no progressive survival period of HER2 -positive breast cancer patients, reducing the risk of progress by 72%, which also means New standards have been here. Recently, among HER2 low -expression patients with advanced breast cancer, the new generation of antibody coupling drugs once again surprises us. This is the first time that HER2 low -expression breast cancer can benefit from the treatment of HER2 , Establish a new concept of breast cancer treatment. But this is not the end. We look forward to the emergence of new target drugs in the future, the combined treatment strategy based on antibody coupling drugs, and look forward to exploring the antibody coupling drug resistance mechanism and solution Continuously deepen, bring greater clinical benefits to patients with tumor patients, and help the achievement of healthy China 2030 goals. "

Professor Ying Jianming said: "From the perspective of pathologists, HER2 is a perfect target for tumor -targeted. First of all, HER2 tests people who are currently paying only on generic amplification in breast cancer and gastric cancer. In addition, HER2 is only expressed in tumor cells, so drugs developed based on HER2 targets are often very effective. The emergence of ADC drugs has put forward new requirements for pathological doctors. Drug therapy HER2 low expression of metastatic breast cancer has opened a new chapter of HER2 low -expression treatment. Past clinical and pathologists only paid attention to HER2 positive, which includes IHC3+and IHC2+and FISH positive, but IHC 0 and IHC 0 and IHC 0 and HER2 low expression IHC 0 and The distinction of 1+ is lacking, so the accuracy of the interpretation of this specimen must be strengthened in the future. Her2 expression is a continuous variable, and the measurement of the effective threshold still needs to be further explored. For example This is a joint cooperation of clinical and pathologists in the future. Looking forward to the future clinical and pathological cooperation, pathological testing promotes more accurate clinical treatment strategies, and the development of clinical treatment promotes the improvement of pathological testing capabilities. "

Summarize

In the journey of fighting malignant tumors, researchers have never stopped, and they continue to explore new treatment strategies. After a century of exploration, the antibody coupling drugs came out. Based on the unique attributes of the structure and mechanism, it gave it to its strong antitumor activity. The clinical benefit was unprecedented, which opened a new chapter in the field of tumor treatment. Especially in the field of HER2 expression of breast cancer treatment, the new generation of ADC drugs not only redefine the new standard for treatment of HER2 -positive breast cancer, but also is expected to become the first targeted drug for HER2 low -expression breast cancer. Of course The increasing attention of China has also brought a lot of challenges to pathology, and it needs to be further explored in the future. However, in general, with the continuous development of antibody coupling drugs, the field of anti -tumor treatment has ushered in a new situation. In the future, more and more tumor patients will be from such high -efficiency and low toxic new drug treatment. Benefiting, thereby helping the realization of the 2030 targets of healthy China.

references

[1]. Heijie. Oncology Introduction [M]. People's Health Press, 2018.

[2] .strebhardt, k. et al. Nature Reviews Cancer8 (6): 473-80

FAQ/LATEST-GLOBAL-CANCER-DATA-2020-QA/

[5] .cardoso f, Senkus E, Costa A, et al. 4th eso-esmo International Conslesus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018 AUG 1; 29 (8): 1634-1657.

Then, then, then

*This article is only used to provide scientific information to medical people, and does not represent the viewpoint of this platform

- END -